Diagnostic Accuracy of MRI in Evaluating Response After Neoadjuvant Systemic Therapy in Operable Breast Cancer

被引:6
|
作者
Khazindar, Abdullah R. [1 ]
Hashem, Dalia Abdulmonem L. [2 ]
Abusanad, Atlal [3 ]
Bakhsh, Salwa, I [4 ]
Bin Mahfouz, Alya [5 ]
El-Diasty, Mohamed T. [5 ]
机构
[1] Univ Jeddah, Dept Radiol, Jeddah, Saudi Arabia
[2] King Faisal Specialist Hosp & Res Ctr, Dept Diagnost Radiol, Jeddah, Saudi Arabia
[3] King Abdulaziz Univ, Dept Med, Jeddah, Saudi Arabia
[4] King Abdulaziz Univ, Dept Pathol, Jeddah, Saudi Arabia
[5] King Abdulaziz Univ Hosp, Dept Radiol, Jeddah, Saudi Arabia
关键词
breast cancer; magnetic resonance imaging; complete pathological response; accuracy; radiological complete response; neoadjuvant chemotherapy; PATHOLOGICAL COMPLETE RESPONSE; CHEMOTHERAPY;
D O I
10.7759/cureus.15516
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Neoadjuvant chemotherapy (NAC) is an important step in the treatment of various types of breast cancer by downsizing the tumor to make it operable. Determining disease extent after NAC is essential for accurate surgical planning. MRI has been the gold standard for detecting tumors that are usually difficult to detect on ultrasound or mammography. However, the use of MRI after NAC is controversial. Therefore, we aimed to evaluate the diagnostic accuracy of post-NAC MRI in the detection of residual disease preoperatively and to investigate the factors associated with pathological complete response (pCR). Methodology This retrospective review study was approved by the institutional review board with waiving of the informed consent. A total of 90 charts between January 2016 and January 2019 were reviewed. Baseline lesion size was measured as the maximal diameter in a single dimension by pretreatment MRI. To assess the diagnostic accuracy of MRI in detecting residual disease, we used two different definitions of pCR in the breast. The first is the resolution of both invasive disease and ductal carcinoma in situ. The second is the resolution of the invasive disease only. As a secondary objective of the study, we assessed the association between different patients' characteristics and both MRI and pathologic response using univariate and multivariate analysis. Results A total of 52 women (mean age: 47.4 years; range: 28-74) with 56 breast masses were eligible for the study. Complete MRI response was noted in 22 ( 39%) masses. pCR was achieved in 14 (25%) and 25 (44.6%) masses using the first and second pCR definitions, respectively. The negative predictive value (NPV) and overall accuracy of MRI for detecting residual disease were 50% and 75%, respectively, using the first pCR definition. With the second pCR definition, NPV and accuracy were 77.3% and 76.8%, respectively. Positive axillary lymph nodes were the only significant factor associated with incomplete MRI and pathological responses. Conclusions MRI NPV for residual disease was higher with the second pCR definition; however, overall accuracy was not different. MRI accuracy in detecting residual disease after NAC is not adequate to replace pathological assessment.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Imaging breast cancer response during neoadjuvant systemic therapy
    Beresford, Mark
    Padhani, Anwar R.
    Goh, Vicky
    Makris, Andreas
    EXPERT REVIEW OF ANTICANCER THERAPY, 2005, 5 (05) : 893 - 905
  • [22] Assessing the accuracy of Magnetic Resonance Imaging (MRI) in evaluating the nodal response to neoadjuvant chemotherapy (NAC) in breast cancer
    Murphy, L. C.
    Razzaq, Z.
    Livingstone, V.
    Redmond, H. P.
    Corrigan, M. A.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2017, 186 : S89 - S89
  • [23] Accuracy of ultrasound in evaluating response to neoadjuvant therapy in invasive lobular carcinoma of the breast
    Fahrner-Scott, Kelly
    Wong, Jasmine M.
    Piper, Merisa
    Ewing, Cheryl
    Alvarado, Michael
    Esserman, Laura J.
    Hylton, Nola
    Mukhtar, Rita A.
    CANCER RESEARCH, 2020, 80 (04)
  • [24] Exploring women's experiences with a decision aid for neoadjuvant systemic therapy for operable breast cancer
    Herrmann, Anne
    Boyle, Frances
    Butow, Phyllis
    Hall, Alix E.
    Zdenkowski, Nicholas
    HEALTH SCIENCE REPORTS, 2018, 1 (01)
  • [25] Women's Experiences with Deciding on Neoadjuvant Systemic Therapy for Operable Breast Cancer: A Qualitative Study
    Herrmann, Anne
    Hall, Alix
    Zdenkowski, Nicholas
    ASIA-PACIFIC JOURNAL OF ONCOLOGY NURSING, 2018, 5 (01) : 68 - 76
  • [26] Patient-reported outcomes with neoadjuvant vs adjuvant systemic therapy for operable breast cancer
    Zdenkowski, Nicholas
    Butow, Phyllis
    Spillane, Andrew
    Douglas, Charles
    Snook, Kylie
    Jones, Mark
    Oldmeadow, Christopher
    Fewster, Sheryl
    Beckmore, Corinna
    Boyle, Frances M.
    BREAST, 2019, 46 : 25 - 31
  • [27] DEVELOPMENT AND TESTING OF A DECISION AID FOR WOMEN CONTEMPLATING NEOADJUVANT SYSTEMIC THERAPY FOR OPERABLE BREAST CANCER
    Zdenkowski, Nicholas
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 102 - 102
  • [28] Exploring how women make decisions on neoadjuvant systemic therapy (NAST) for operable breast cancer
    Herrmann, A.
    Hall, A.
    Zdenkowski, N.
    BREAST, 2016, 29 : S27 - S27
  • [29] Neoadjuvant Therapy in Operable Breast Cancer: Application to Triple Negative Breast Cancer
    Ademuyiwa, Foluso O.
    Ellis, Matthew J.
    Ma, Cynthia X.
    JOURNAL OF ONCOLOGY, 2013, 2013
  • [30] Neoadjuvant systemic therapy for breast cancer
    Zaborowski, Alexandra M.
    Wong, Stephanie M.
    BRITISH JOURNAL OF SURGERY, 2023, 110 (07) : 765 - 772